A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
← catalyst calendarNCT05811416 · readout in 154 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
200estimated
Sites
1
Country
Spain
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-06-14 | actual | When the study began enrolling |
| Primary completion | 2027-01-20 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-01-20 | estimated | The whole study's end, after follow-up |
| First posted | 2023-04-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Relapsing-remitting Multiple Sclerosis (RRMS)
Primary outcomes
what the primary-completion date above is the date OFTime from ozanimod treatment initiation to ozanimod treatment permanent discontinuation
measured Up to 24 months
Percentage of participants on treatment with ozanimod at 24 months
measured At month 24
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed